Associated Genetic Biomarkers
NCI Definition: A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood. Sezary syndrome is an aggressive disease. (WHO, 2001) 
Sezary syndromes most frequently harbor alterations in SETD1B, PLCG1, FAS, UBR5, and TP53 .
SETD1B Loss, PLCG1 S345F, UBR5 R1379W, UBR5 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in sezary syndrome .
There are 23 clinical trials for sezary syndrome, of which 20 are open and 3 are completed or closed. Of the trials that contain sezary syndrome as an inclusion criterion, 10 are phase 1 (8 open), 5 are phase 1/phase 2 (4 open), 7 are phase 2 (7 open), and 1 is phase 3 (1 open).
TNFRSF8, CD4, and CD5 are the most frequent gene inclusion criteria for sezary syndrome clinical trials .
Mogamulizumab, pembrolizumab, and bendamustine are the most common interventions in sezary syndrome clinical trials.
Significant Genes in Sezary Syndrome
ALK is an inclusion eligibility criterion in 1 clinical trial for sezary syndrome, of which 1 is open and 0 are closed. Of the trial that contains ALK status and sezary syndrome as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.